Adjuvance announce clinical results of its next-gen saponin adjuvant
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
The company to receive upfront and milestone payments, in addition to royalties
In the last two years, Sai Life Sciences has made significant investments and progress in advancing its sustainability agenda as part of its organizational transformation initiative
Domestic business was up 41.9% YoY and 27.7% QoQ
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Floods had forced the plans in Mahad to shut down
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
Zydus was the first to file an ANDA for Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength
The vaccine will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of Covid-19 disease
Subscribe To Our Newsletter & Stay Updated